Volex PLC, a UK manufacturer of power and data transmission products, reported a record first-half revenue increase of at least 21% to $710 million for the six months ending September 30, 2026. Growth was driven by aerospace, defence, electric vehicles, electrification, and consumer electricals, with a notable contribution from its recent acquisition, Kepler SignalTek. The company expects its annual operating profit to reach the upper end of market forecasts, with margins improving toward a 12% medium-term target due to a stronger sales mix and operational efficiencies. Volex also plans to complete US manufacturing site consolidation by year-end and anticipates further growth from next-generation data centre products starting in fiscal 2028. Half-year results will be published on November 12.
Volex's record first-half revenue growth of at least 21% to $710 million sets a strong performance benchmark. For readers following Industrials-sector US stocks on Pluang, here is the market snapshot as of Oct 19, 2026 13:41 WIB: out of 135 stocks, 102 rose and 32 fell. Notable movers include SMX Security Matters plc (SMX) up 7.57% at USD 1.99 with a typical hold time of 22 days, Geo Group Inc (GEO) down 6.98% at USD 28.66 with a typical hold time of 10 days, and Nordic American Tankers Limited (NAT) down 6.46% at USD 7.68 with a typical hold time of 4 days.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
